Armata Pharmaceuticals Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARMP American 2836 https://www.armatapharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Armata Pharmaceuticals Inc

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update - Mar 16th, 2023 8:10 pm
Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis - Mar 6th, 2023 11:00 am
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC - Jan 10th, 2023 9:05 pm
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - Dec 22nd, 2022 1:00 pm
Armata Pharmaceuticals, Inc. (ARMP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Dec 8th, 2022 2:55 pm
After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP) - Nov 28th, 2022 2:35 pm
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage - Nov 28th, 2022 1:00 pm
Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing - Nov 15th, 2022 2:55 pm
Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update - Nov 9th, 2022 9:15 pm
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update - Aug 11th, 2022 8:05 pm
Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections - Aug 1st, 2022 12:00 pm
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus - May 23rd, 2022 12:00 pm
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update - May 12th, 2022 8:17 pm
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva - Mar 31st, 2022 8:05 pm
Wall Street Analysts See a 52% Upside in Armata Pharmaceuticals, Inc. (ARMP): Can the Stock Really Move This High? - Mar 22nd, 2022 2:00 pm